Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET

Tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) are effective in most NSCLC patients whose tumors harbor activating EGFR kinase domain mutations. Unfortunately, acquired resistance eventually emerges in these chronically treated cancers. Two of the most comm...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Xu, Lu, Kikuchi, Eiki, Xu, Chunxiao, Ebi, Hiromichi, Ercan, Dalia, Cheng, Katherine A., Padera, Robert, Engelman, Jeffrey A., Jänne, Pasi A., Shapiro, Geoffrey I., Shimamura, Takeshi, Wong, Kwok-Kin
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3389159/
https://ncbi.nlm.nih.gov/pubmed/22552292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-3720
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares